KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Non-Current Deffered Revenue: 2013-2025

Historic Non-Current Deffered Revenue for Sarepta Therapeutics (SRPT) over the last 5 years, with Mar 2025 value amounting to $325.0 million.

  • Sarepta Therapeutics' Non-Current Deffered Revenue changed negligibly% to $325.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $325.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $325.0 million for FY2024, which is 25.63% down from last year.
  • According to the latest figures from Q1 2025, Sarepta Therapeutics' Non-Current Deffered Revenue is $325.0 million, which was down 0.00% from $325.0 million recorded in Q4 2024.
  • Over the past 5 years, Sarepta Therapeutics' Non-Current Deffered Revenue peaked at $641.5 million during Q1 2021, and registered a low of $325.0 million during Q1 2024.
  • In the last 3 years, Sarepta Therapeutics' Non-Current Deffered Revenue had a median value of $325.0 million in 2025 and averaged $390.8 million.
  • Data for Sarepta Therapeutics' Non-Current Deffered Revenue shows a maximum YoY tumbled of 32.99% (in 2024) over the last 5 years.
  • Sarepta Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $574.2 million in 2021, then declined by 15.54% to $485.0 million in 2022, then fell by 9.90% to $437.0 million in 2023, then declined by 25.63% to $325.0 million in 2024, then remained steady at $325.0 million in 2025.
  • Its last three reported values are $325.0 million in Q1 2025, $325.0 million for Q4 2024, and $325.0 million during Q3 2024.